
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Leflunomide
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Wanbang’s Leflunomide Tablets Get FDA Nod, Set to Enter U.S. Market
Details : Leflunomide is an immunomodulatory drug that inhibits the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH), in patients with rheumatoid arthritis.
Product Name : Leflunomide-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 12, 2020
Lead Product(s) : Leflunomide
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
